Read the complete earnings call transcript with search and download options.
NeuroOne Medical Technologies Corp reported a highly successful fiscal year 2025, with record product sales growth of 163% to $9.1 million. The company achieved significant improvements in product gross margins and reduced operating expenses. Key developments included FDA clearances and successful treatments using the 1RF trigeminal nerve ablation system, alongside advancements in their spinal cord stimulation and drug delivery programs. Strategically, NeuroOne is strengthening partnerships, including collaborations with Zimmer Biomet and the CURE epilepsy organization, to enhance market visibility and leverage technology for new treatments, particularly in pain management. The focus remains on further expanding the product portfolio and obtaining FDA approvals for commercial readiness in 2026. During the Q&A session, analysts expressed interest in the continued rollout of the trigeminal nerve ablation system and potential strategic partnerships. NeuroOne's leadership displayed confidence in their ability to achieve operational and revenue goals, supported by a strong financial position entering the next fiscal year.
Fiscal year 2025 was the most successful year in NeuroOne's history, with record product sales growth of 163% to $9.1 million.
In Q4 2025, NeuroOne's product revenue soared 907% to $2.7 million, and product gross margins rose to 55.8%.
FDA 510K clearance received for 1RF trigeminal nerve ablation system; first two patients were successfully treated.
Product revenue for fiscal year 2025 increased 163% to $9.1 million compared to $3.5 million for fiscal year 2024.
NeuroOne has partnered with CURE and the Epilepsy Foundation to make their therapy more visible to patients.
Two active programs in development for treating lower back pain using innovative electrode technologies.
NeuroOne is engaging with strategic partners to leverage existing technology for lower back pain treatment.
Product Revenue
$2.7 million
+907% YoY
Product Revenue
$9.1 million
+163% YoY
Product Gross Margin
55.8%
+4% pts YoY
Operating Expenses
$2.9 million
-2% YoY
Net Loss
$1.6 million
Improved by 52% YoY